The impact of COVID-19 on the health plan enterprise appears to be practical and functional rather than strategic and financial.
Ira Studin, PhD, MPH
Advertisement
Articles by Ira Studin, PhD, MPH
The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.
Oncology economics is the product of driving forces in the health insurance market that are intrinsic to oncology in managed care and unlikely to change.
Advertisement
Latest Updated Articles
Boomerang Effect Of Gene Therapy on Oncology ContractingPublished: February 11th 2019 | Updated:
May 2020 Snapshot: The Impact of COVID-19 on Health Plans From a Pharmacy Point-of-ViewPublished: May 14th 2020 | Updated:
Oncology EconomicsPublished: May 15th 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
2
Breaking News: CVS Buys Rite Aid, Bartell Drugs
3
FDA Approves 1-Minute HIV Self-Test
4
Study: APOL1 Mutations in CKD Significantly Affect Cells Crucial to Kidney Function
5
